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Abstract
Introduction: Background to metabolomics Metabolomics
is the comprehensive study of the metabolome, the reper-
toire of biochemicals (or small molecules) present in cells,
tissues, and body fluids. The study of metabolism at the
global or ‘‘-omics’’ level is a rapidly growing field that has
the potential to have a profound impact upon medical
practice. At the center of metabolomics, is the concept that
a person’s metabolic state provides a close representation
of that individual’s overall health status. This metabolic
state reflects what has been encoded by the genome, and
modified by diet, environmental factors, and the gut
microbiome. The metabolic profile provides a quantifiable
readout of biochemical state from normal physiology to
diverse pathophysiologies in a manner that is often not
obvious from gene expression analyses. Today, clinicians
capture only a very small part of the information contained
in the metabolome, as they routinely measure only a
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narrow set of blood chemistry analytes to assess health and
disease states. Examples include measuring glucose to
monitor diabetes, measuring cholesterol and high density
lipoprotein/low density lipoprotein ratio to assess cardio-
vascular health, BUN and creatinine for renal disorders,
and measuring a panel of metabolites to diagnose potential
inborn errors of metabolism in neonates.
Objectives of White Paper—expected treatment outcomes
and metabolomics enabling tool for precision medicine We
anticipate that the narrow range of chemical analyses in
current use by themedical community todaywill be replaced
in the future by analyses that reveal a far more comprehen-
sive metabolic signature. This signature is expected to
describe global biochemical aberrations that reflect patterns
of variance in states of wellness, more accurately describe
specific diseases and their progression, and greatly aid in
differential diagnosis. Such future metabolic signatures will:
(1) provide predictive, prognostic, diagnostic, and surrogate
markers of diverse disease states; (2) inform on underlying
molecular mechanisms of diseases; (3) allow for sub-clas-
sification of diseases, and stratification of patients based on
metabolic pathways impacted; (4) reveal biomarkers for
drug response phenotypes, providing an effective means to
predict variation in a subject’s response to treatment (phar-
macometabolomics); (5) define a metabotype for each
specific genotype, offering a functional read-out for genetic
variants: (6) provide a means to monitor response and
recurrence of diseases, such as cancers: (7) describe the
molecular landscape in human performance applications and
extreme environments. Importantly, sophisticated metabo-
lomic analytical platforms and informatics tools have
recently been developed that make it possible to measure
thousands of metabolites in blood, other body fluids, and
tissues. Such tools also enable more robust analysis of
response to treatment. New insights have been gained about
mechanisms of diseases, including neuropsychiatric disor-
ders, cardiovascular disease, cancers, diabetes and a range of
pathologies. A series of ground breaking studies supported
by National Institute of Health (NIH) through the Pharma-
cometabolomics Research Network and its partnership with
the Pharmacogenomics Research Network illustrate how a
patient’s metabotype at baseline, prior to treatment, during
treatment, and post-treatment, can inform about treatment
outcomes and variations in responsiveness to drugs (e.g.,
statins, antidepressants, antihypertensives and antiplatelet
therapies). These studies along with several others also
exemplify how metabolomics data can complement and
inform genetic data in defining ethnic, sex, and gender basis
for variation in responses to treatment, which illustrates how
pharmacometabolomics and pharmacogenomics are com-
plementary and powerful tools for precision medicine.
Conclusions: Key scientific concepts and recommendations
for precision medicine Our metabolomics community
believes that inclusion of metabolomics data in precision
medicine initiatives is timely and will provide an extremely
valuable layer of data that compliments and informs other data
obtained by these important initiatives. Our Metabolomics
Society, through its ‘‘Precision Medicine and Pharma-
cometabolomics Task Group’’, with input from our metabo-
lomics community at large, has developed this White Paper
where we discuss the value and approaches for including
metabolomics data in large precision medicine initiatives.
ThisWhite Paper offers recommendations for the selection of
state of-the-art metabolomics platforms and approaches that
offer the widest biochemical coverage, considers critical
sample collection and preservation, as well as standardization
of measurements, among other important topics. We antici-
pate that our metabolomics community will have represen-
tation in large precision medicine initiatives to provide input
with regard to sample acquisition/preservation, selection of
optimal omics technologies, and key issues regarding data
collection, interpretation, and dissemination. We strongly
recommend the collection and biobanking of samples for
precision medicine initiatives that will take into consideration
needs for large-scale metabolic phenotyping studies.
Keywords Metabolomics  Metabonomics 
Pharmacometabolomics  Pharmacometabonomics 
Precision medicine  Personalized medicine
1 Introduction
In 2016, theWhite House announced the precision medicine
initiative (PMI) in the USA to help enable a new era of
individualized care through cooperative efforts by
researchers, providers, and patients. The National Institutes
of Health and its director Francis Collins have called for
communities of researchers from around the country tomake
the case as to what set of technologies and disciplines would
afford the highest level of efficacy in the development of the
PMI. An enabling structure for this initiative has been cre-
ated and partially funded (https://www.nih.gov/precision-
medicine-initiative-cohort-program; Collins and Varmus
2015). Metabolomics offers a powerful set of tools, strate-
gies, and methods necessary for the generation of complex
and robust data sets, which complement data obtained by
genomics and other omics methodologies and that uniquely
captures effects of environment, exposome, gut microbiome
and genome on human health. The Metabolomics Society’s
Precision Medicine and Pharmacometabolomics Task
20 Psychiatry and Behavioral Sciences, Duke Internal Medicine
and Duke Institute for Brain Sciences and Center for Applied
Genomics and Precision Medicine, Duke University Medical
Center, Box 3903, Durham, NC 27710, USA
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Group herein provides a rationale as to whymetabolomics is
a vital and necessary component of the PMI, and for all
global precision medicine initiatives going forward.
The phenotypic outcome of the complex interactions
between genotype, lifestyle, diet, nutrition, drug therapy,
environmental exposure, and gut microflora can now be
investigated at the molecular level by identifying and
quantifying a broad range of endogenous and exogenous
metabolites (Fig. 1). Such metabolic phenotyping studies
are able to provide new insights into disease pathophysi-
ology, and mechanisms that underlie differences in drug
responses in the human population, which contribute to
predicting both risk of toxicity and beneficial responses to
drug treatment (Beger et al. 2015; Cacciatore and Loda
2015; Everett 2015; Kaddurah-Daouk et al. 2008; Kaddu-
rah-Daouk and Weinshilboum 2014, 2015; Kastenmu¨ller
et al. 2015; Nicholson et al. 2012; Patti et al. 2012; Su et al.
2014; Suhre et al. 2016; Wilson 2009; Zamboni et al.
2015). Below we provide background information, con-
cepts related to the use of metabolism data for disease and
patient sub-classification, technologies that are available
for metabolic profiling, their strengths, limitations and
bottlenecks, and presently available tools for large scale
studies in precision medicine. We highlight how the
metabolome complements and reveals details about the
downstream effects of the genome, how it can describe the
real-time activity of the gut microbiome, the broad effects
of environmental influences that impact human health, and
individual responses to treatment.
2 Background
2.1 Metabolomics and the Central Dogma
Recognition of the Central Dogma of molecular biology had
a major impact in the life sciences. Indeed, an appreciation
for the fact that life arises from chromosomal DNA being
transcribed into RNA, which is in turn translated into
functional proteins, affords a molecular explanation for the
basis of life. It also provided molecular insights into the
inherent variation in human susceptibility to diseases and for
the differential efficacy of therapeutic drugs in patients.
However, the Central Dogma fails to consider that the actual
function of genes, transcripts, and proteins is specifically to
control the small molecule composition of cells. It is these
small molecules that carry out the main work of functioning
cells, including regulating the activity of the macro-
molecules in a complex feedback circuit (Fig. 1). Indeed, it
is the interactions of the small molecules with the macro-
molecular components of the cell that comprise the main
determinants of cell function and dysfunction.
Fig. 1 Metabolomics, a global biochemical approach for disease sub classification and drug response phenotyping
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Importantly, the metabolome is dynamic and rich, aris-
ing only partially as the product of our own gene-encoded
proteins. It also arises from the metabolic products of the
microbes within us, the air we breathe, the food we eat, and
the water we drink (Nicholson et al. 2004; Goodacre 2007;
Scalbert et al. 2009; Lindon and Nicholson 2014). The
metabolome is thus, incompletely defined and cannot be
predicted from knowledge of the human genome, tran-
scriptome, or proteome alone. Yet, despite this complexity
and its associated technical challenges to comprehensive
quantification, we posit that the metabolome offers the
most revealing real time insights toward understanding
human disease heterogeneity and variation in response to
treatment, and does so at a systems level. It captures
important influences on human health that go beyond the
genome.
Recent technological breakthroughs have now enabled
broad and confident quantification of hundreds of
metabolites or relative quantification of thousands of dis-
tinct metabolites in complex biological mixtures (e.g.,
blood and urine). This capability advances a powerful new
analytical reality of untargeted metabolite profiling. With
the continuing scale-up of current technologies, bolstered
by further technological advances on the near horizon, we
posit that comprehensive metabolite profiling, applied to
samples from large initiatives like the NIH precision
medicine initiative cohort (PMI), will provide perhaps one
of the most valuable tools for patient stratification, further
enabling the promise of precision medicine. Accordingly,
to obtain optimal return on investment in large precision
medicine initiatives, it is critical that metabolomic analyses
be included. While the inclusion of metabolomics could be
staged over time, we urge that samples for current studies
be collected in a manner that meets metabolomic profiling
needs (sample collection, preparation, and storage).
2.2 Metabotyping is currently used to screen
for inborn errors of metabolism
Metabolism data and inclusion of a targeted metabolic
profile in blood has led to the identification of many inborn
errors of metabolism (IEMs), a group of monogenetic
metabolic disorders that can be lethal in newborns, or result
in irreversible organ damage, if not diagnosed and treated
swiftly. However, if IEMs are recognized by early
screening, many can be controlled with life-saving nutri-
tional supplements and dietary interventions. Using current
metabolite profiling platforms, which can now survey
thousands of metabolites in microliter quantities of
neonatal blood, we anticipate an enormously expanded
scope of IEM diagnosis and the discovery of previously
unrecognized genetic diseases in the near-term (Schulze
et al. 2003; Vernon 2015; Yoon 2015).
2.3 Metabotypes for genotypes—the metabolome
provides a readout for functions of genetic
variants
Over 100 years ago, Archibald Garrod conjectured that
‘‘inborn errors of metabolism’’ are ‘‘merely extreme
examples of variations of chemical behavior which are
probably everywhere present in minor degrees’’ and that
this ‘‘chemical individuality predisposition to and immu-
nities from the various mishaps which are spoken of as
diseases’’. Population based studies collected demographic,
health and life-style related information from thousands of
individuals from the general population, and bio-banked
samples of blood, urine, and other body fluids are now
analyzed using genomics, transcriptomics, proteomics,
metabolomics and other large scale omics technologies
(Kastenmu¨ller et al. 2015; Sanseau et al. 2012; Shin et al.
2014; Suhre et al. 2011a, b, 2016; Suhre and Gieger 2012).
These studies have proven Garrod’s conjecture in many
instances, showing how genetic predisposition interacts
through intermediate metabolic phenotypes with environ-
mental factors and lifestyle choices in the pathogenesis of
complex disorders. Figure 2 gives an example of a genet-
ically influenced metabotype (GIM). To date, over 150
such GIMs have been discovered (Kastenmu¨ller et al.
2015) and are now being used to dissect the genetic and
environmental factors that trigger complex disorders
(Fig. 3). We anticipate that deep metabolic phenotyping of
the precision medicine initiative cohort program (and other
precision medicine initiatives) will confidently identify
fundamental factors in the development of major diseases,
lead to the discovery of new biomarkers, and reveal novel
targets for clinical intervention. A comprehensive blueprint
of human metabolic pathways and linkage to genes and
their expression, such as the global human metabolic net-
work (Thiele et al. 2013) that had been created by the
systems biology community, would inform strategies for
modifying dysregulated metabolites in a rational and tar-
geted manner, potentially using drugs that are pre-existing
and safe—as suggested by recent genome-wide association
study (GWAS) findings (Sanseau et al. 2012).
In summary, the metabolome provides a read out for
functions of genetic variants associated with human disease
and great mechanistic insights about pathways implicated
in disease, disease heterogeneity, disease progression and
variation in response to treatment.
2.4 Pharmacometabolomics: a detailed biochemical
roadmap for defining disease heterogeneity
and drug response variation
With significant funding from the National Institute of Gen-
eral Medical Sciences (NIGMS), the Pharmacometabolomics
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and Pharmacogenomics Research Networks (PGRN and
PMRN) have interacted closely over the past 8 years and
pioneered how genetic and metabolic data alone, or in com-
bination can inform about treatment outcomes and mecha-
nisms that underlie variation in response to treatments. Over
ten classes of therapieswere studied in patients to illustrate the
concept and its generalizability in human studies for precision
medicine approach. This along with few other studies estab-
lished key concepts and foundations for this new field Phar-
macometabolomics (also known as Pharmacometabonomics)
Table 1. A historic study in animals by Imperial researchers
and their pharmaceutical consortium revealed how metabo-
lomics data at baseline can inform about drugmetabolism and
toxicity (Clayton et al. 2006).
Pharmacometabolomics evolved as a field that deter-
mines the so-called ‘‘metabotype’’ or metabolic state of an
individual as affected by environmental, genetic, and
enteric microbiome influences (Fig. 1) to study drug
responses and to understand treatment outcomes. Meta-
bolic profiles at baseline prior to treatment were shown to
inform about disease heterogeneity and treatment out-
comes. Also metabolic profiles provide tools for mapping
global effects of drugs on metabolism, and for identifying
pathways and networks implicated in the mechanisms of a
drug’s action and the basis for variation in drug responses.
Examples of totally novel insights about mechanisms of
variation of response to drugs used for treatment of neu-
ropsychiatric and cardiovascular diseases were highlighted
in recent reviews (Kaddurah-Daouk and Weinshilboum
2014, 2015). Metabolic profiles were shown to provide
insights about variation of response to antipsychotics, sta-
tins, antidepressants, antihypertensives, antiplatelet thera-
pies, and development of side effects to treatment. A first
validation study in humans mapped effects of three
Fig. 2 Example of a genetically influenced metabotype (GIM). Fatty
acid desaturase 1 (FADS1) catalyzes the desaturation of dihomoli-
nolenoyl-CoA to arachidonoyl-CoA (C20:3 to C20:4). Minor allele
homozygotes (7.6 % of the population) of the rs174548 variant
convert C20:3 to C20:4 poly-unsaturated fatty acids (PUFAs) about
50 % slower than homozygous carriers of the major allele (52.6 % of
the population). The FADS locus has been implicated in multiple
GWAS with different cancers, Crohn’s disease and cardiovascular
disease traits. This example shows how genetic variance in metabolic
traits can be linked to complex disorders to provide a functional
understanding of the underlying disease mechanism. Figure from
Suhre et al. 2016
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antipsychotics in patients with schizophrenia, compared
their effects on metabolism and defined signature at base-
line implicated in treatment outcomes (Kaddurah-Daouk
et al. 2007). The mapping of depressed patient’s metabo-
types and the trajectory of biochemical changes induced by
SSRI antidepressants (serotonin reuptake inhibitors) have
since begun to explain the biochemical basis for delayed
response, responses to placebo, and resistance to treatment
in major depression. Ethnic basis for variation in response
to antihypertensives (beta blockers and thiazide) and gen-
der differences in response to antiplatelet therapies
(aspirin) provided first examples of how metabolomics data
combined with genetic data could start to define factors that
contribute to variation in response to treatment. An
important role for the gut microbiome was highlighted by
the variation of response to statins (Kaddurah-Daouk et al.
2011b) and for acetaminophen (Clayton et al. 2006, 2009;
Winnike et al. 2010). These studies as well as several
others applied to the study of cancer chemotherapies
(Backshall et al. 2011; Miolo et al. 2016; Stebbing et al.
2012) and others under pharmacometabonomics (for
review see Everett et al. 2013; Everett 2015; Huang et al.
2015) all provide support for importance of inclusion of
metabolomics data in precision medicine initiatives
(Table 1). Metabolomics data captures influences on
human health that go beyond genetic makeup.
Metabolomics also has a great potential to be introduced
directly into the clinic, as a key profiling and phenotyping
platform used to predict patients’ responses to different
treatments. This can lead to development of decision sup-
port tools for patients and clinicians for the purpose of
selecting or recommending optimal treatment regimens (to
be used in broad sense of the word, thus including also
lifestyle changes). The expectation is that, by using the
‘personalized profiles,’ we will be able to circumvent the
commonly applied treatment-failure approach and, thus,
ultimately contribute to better patient outcomes (Fig. 4).
2.5 The gut microflora influence human metabolism
and a metabolic profile informs about gut
microbiome activity
The human gut microbiome is known to possess metabolic
activity considered comparable to that of the liver. The
composition of the gut microbiome has wide ranging local
and systemic effects. As such, it has been implicated in
local disorders, such as inflammatory bowel disorders and
an array of systemic conditions, including, but not limited
to, disorders of the nervous, cardiovascular, and immune
systems (Table 2). Microbiome-associated metabolomics
has been employed to investigate and characterize a range
of clinically relevant features. In this regard, it is generally
considered useful to characterize both the (1) stool/gut
metabolome and microbiome, in combination with (2) a
readout of the host’s systemic metabolome (e.g., biofluids
such as blood, urine and saliva). Clinically-relevant and
notable applications of metabolomics to gut microbiome
activity are noted below in Table 2.
Thus, the metabolomics task group recommends at least
one urine and one fecal sample to be collected from a
subset of individuals enrolled in the PMI Cohort and other
similar initiatives to evaluate gut microbiome metabolic
activity. These samples would ideally be acquired follow-
ing an overnight fast. Further samples, collected from a
subset of the population at selected serial time points would
be extremely useful for monitoring responses to
Fig. 3 The metabolic trait is an intermediate phenotype that links the
genome, lifestyle and environmental factors to the clinical endpoint.
The general concept (a) and an example using information from
actual genome-wide association studies with metabolic traits (b). The
association of a genetic variant is strongest with its closest interme-
diate phenotype [IP; for example, the association of fatty acid
desaturase 1 (FADS1) with its product–substrate pair], while the
association with the clinical end point may be hard to detect at a level
of genome-wide significance in a GWAS (P = 0.021 for FADS1 with
coronary heart disease). The ensemble of all genetic associations with
metabolic traits defines our metabolic individuality and thereby our
predisposition to disease. Deep metabolic phenotyping of large
precision medicine initiatives allows to identify key factors for the
development of complex disorders, which can then serve as
biomarkers and targets for clinical intervention. Figure reproduced
from Suhre and Gieger 2012
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environmental perturbations, e.g. how the gut microbiome
is affected by cognate drug treatments.
2.6 Nutrition-associated metabolic phenotyping
Metabolomics in a nutritional context has already been
employed to investigate and characterize relevant fea-
tures of the metabolic phenotype. Furthermore, diet
remains a key environmental factor that needs to be
characterized in order to understand its relationship to
disease, and to develop a clear and confident public
health message in relation to disease prevention. Dis-
ease nutrition relationships through metabolomics is not
only useful for increasing our understanding of pathol-
ogy, but also for understanding how the knowledge of
metabolism can be employed as a key factor in disease
prevention, as well as to optimize human function and
performance.
Table 1 Clinically-relevant and notable applications of pharmacometabolomics
Applications Citations
Pharmacometabonomics signature predictive of drug metabolism and development of side effects
to acetaminophen—role for gut microbiome
Clayton et al. 2006, 2009; Winnike et al.
2010
Metabolomics lipidomics mapping of atypical antipsychotics and baseline signature of response to
three antipsychotics
Kaddurah-Daouk et al. 2007
Pharmacometabolomics and lipidomics reveals large impact of statin on lipid metabolism; lipid
profile at baseline informs about treatment response that goes beyond HMGCoA reductase
inhibition
Kaddurah-Daouk et al. 2010
Pretreatment metabotype as a predictor of response to antidepressant sertraline and response to
placebo in depressed outpatients
Kaddurah-Daouk et al. 2011a
Gut microbiome contributes to response to simvastatin Kaddurah-Daouk et al. 2011b
Pharmacometabolomics-informed pharmacogenomics Ji et al. 2011
Pharmacometabolomics for cancer chemotherapies Backshall et al., 2011; Stebbing et al. 2012;
Miolo et al. 2016
Pharmacometabolomics of statin response reveals novel mechanistic insights and highlights
metabolic signature for poor response
Trupp et al. 2012
Merging pharmacometabolomics with pharmacogenomics using ‘1000 Genomes’ single-
nucleotide polymorphism imputation to define drug response variation to SSRI antidepressants
Abo et al. 2012
Pharmacometabolomic signatures of response to antidepressant sertraline and to placebo; insights
on biochemical basis for response to placebo; biochemical insights for delayed response to SSRIs
Kaddurah-Daouk et al. 2013
Pharmacometabolomics of statin response review Krauss et al. 2013
Pharmacometabolomics of antiplatelet therapies review Lewis et al. 2013
Pharmacometabolomics reveals biochemical insights about ethnic differences in response to beta
blocker atenolol
Wikoff et al. 2013
Pharmacometabolomics pharmacogenomics approach highlights purine pathway enzymes and
genes implicated in mechanism of variation of response to aspirin
Yerges-Armstrong et al. 2013
Reviews of published work in pharmacometabolomics/pharmacometabonomics; additional
references within
Wilson 2009, Everett et al. 2013; Everett
2015
Review on pharmacometabolomics a systems pharmacology approach for precision medicine Kaddurah-Daouk et al. 2014
Pharmacometabolomics reveals a diabetes mellitus-linked amino acid signature associated with b-
blocker-induced impaired fasting glucose levels
Cooper-Dehoff et al. 2014
Pharmacometabolomics reveals a role for serotonin in mechanism of varied response to aspirin
treatment
Ellero-Simatos et al. 2014
Targeted lipidomics profile of aspirin’s effect on oxylipid metabolism, new mechanistic insights
about response to aspirin and off target effects
Ellero-Simatos et al. 2015
Review on pharmacometabolomics enabling tools for precision medicine Kaddurah-Daouk and Weinshilboum 2015
Pharmacometabolomic assessments of antihypertensives atenolol and hydrochlorothiazide
pathways implicated in response; common and unique mechanisms
Rotroff et al. 2015
Pharmacometabolomics-informed pharmacogenomics about response to SSRI sertraline; metabolic
signatures helped identify genes and SNPs implicated in response variation and disease sub
classification
Gupta et al. 2016
Pharmacometabolomic assessment of metformin PK profile; pharmacometabolic signature
informing about PK profile of drug
Rotroff et al. 2016
Insights from genomics and metabolomics integration on response to antihypertensives; a systems
pharmacology approach for precision medicine
Shahin et al. 2016
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Assessing dietary input accurately is difficult-most
studies rely on surrogate methods based on questionnaires,
which are notoriously unreliable (Dhurandhar et al. 2015).
A metabolic profile of blood and urine contains biomarker
information that can, in fact, provide a far more accurate
estimate of dietary inputs, which can also correct misre-
porting on questionnaires. There is ample evidence for the
importance of diet in health and disease. Obesity and adi-
posity have numerous effects on health including CVD and
some cancers. For example, adiposity is a significant risk
factor for colorectal cancer, which is higher in males than
females, and is also linked to diet. Diets rich in red or
processed meats increase the risk of colorectal cancer in
particular (http://www.cancer.gov/about-cancer/causes-pre
vention/risk/obesity/obesity-fact-sheet#q6).
Therefore, nutritional metabolomics investigations fall
into three major experimental categories: (A) applications
to identify dietary biomarkers (B) applications to study
metabolic responses to dietary interventions and (C) appli-
cations to study diet-related diseases. All of these appli-
cations can deliver further information on the impact of one
of the key modifiable environmental factors (diet). Some
notable applications of this approach are enumerated in
Table 3.
3 Metabolic profiling technologies
The revolution in the study of metabolites in the last
15 years and the development of the field of metabolomics
has resulted from innovative advances in scientific instru-
mentation and advances in computational resources avail-
able. The continued development of chromatography
coupled to mass spectrometry (MS) and nuclear magnetic
resonance (NMR) spectroscopy have advanced our capa-
bilities from monitoring only a small number of metabo-
lites in a traditional hypothesis-testing study, to being able
to simultaneously quantify hundreds to thousands of
metabolites in a biological sample with an analysis time of
less than 20 min (Cajka and Fiehn 2014; Fiehn 2016). This
enormous new analytical capability has led to the genera-
tion of novel and completely unanticipated hypotheses
(Dunn et al. 2011)—effectively shining light in places
where nobody previously though to look. We define this
non-targeted approach as metabolic phenotyping
(‘‘metabotyping’’).
Importantly, metabotyping can provide important data
not only on the metabolites present in a complex biological
mixture, but also reveal molecular interactions that con-
tribute to metabo-regulatory processes in cells and tissues.
Only through the application of such holistic approaches,
as a first step, can the complete biological interactome be
defined in relation to human phenotypes. Once specific
metabolic markers are identified, further studies applying
targeted assays can be performed in attempt to validate
findings and test novel hypotheses that emerge. Recent
translational studies illustrate how metabotyping can lead
to new and fundamental biomedical discoveries (Gooding
et al. 2015; Tannahill 2013).
The current capabilities for holistic metabolic profiling
apply liquid chromatography and gas chromatography
coupled to mass spectrometry (GC–MS and LC–MS), as
well as NMR spectroscopy. The stability and repro-
ducibility of these platforms is hugely important in large-
scale cohort studies and recent research has shown the
capability now exists for robust and high quality data
generation (Draisma et al. 2015; Dunn et al. 2015). This
has allowed us to move from small-scale studies to large-
Fig. 4 Precision medicine approach using metabolomics as com-
pared to treatment-failure evidence-based medicine approach in
clinical practice. ‘Personalized profile’ based on metabolomics as
well as other clinical and lifestyle data will be used to predict the
patients’ responses to specific treatments and thus help select the best
treatment regimens
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scale investigations that may include thousands of samples.
Indeed, a number of ‘Phenome Centers’ are being devel-
oped to provide the infrastructure and resources required to
support large-scale studies (e.g., the National Phenome
Centre in London; the Phenome Centre Birmingham UK;
six NIH Regional Comprehensive Metabolomics Resour-
ce Cores in the USA and large consortia, such as Alzhei-
mer Disease Metabolomics). Standardization of analyses
performed at these centers will be a challenge, but recog-
nized as essential to allow data to be comparable and
Table 2 Clinically-relevant and notable applications of gut microbiome-associated metabolomics
Applications Citations
Generating new hypotheses related to health and patterns of disease Nicholson et al. 2005
Assessing the effect of dietary inputs on the microbiome/metabolome (protein, CHO, fat, polyphenols,
etc.)
Purnbaugh and Gordon 2008;
Moco et al. 2012
Identifying individual patterns of drug susceptibility, based on gut-associated metabolite patterns (e.g.,
urine p-cresol)
Clayton et al. 2009
Correlating the fecal metabolome with blood and urine metabolome to understand better peripheral
markers of gut microbial metabolism
Jansson et al. 2009
Assessing the role of the microbiome in metabolizing dietary constituents to metabolically active
molecules with clinical benefit (e.g., lignans and enterolactone-endocrine effects)
Peterson et al. 2010
Assessing the impact of drugs on the microbiome/metabolome (e.g., antibiotics) Hviid et al. 2011
A role for the gut microbiome in mechanism of variation of response to statins Kaddurah-Daouk et al. 2011b
Assessing the impact of the gut microbiome on the metabolism of prescription drugs (e.g., b-
glucuronidases; effects on antibiotics, antivirals, anti-inflammatories, and anticonvulsants)
Cacciatore and Loda 2015
Assessing the effect of dietary inputs on the microbiome/metabolome relative to disease endpoints (e.g.,
choline, trimethylamine oxide, and CVD)
Mente et al. 2015
Correlating gut microbial genotype with small molecule molecular phenotype Xie and Jia 2015
Correlating the gut microbial metabolome with the exposome Patel and Manrai 2015
Understanding the patterns of microbiome-derived small molecules that enter systemic circulation Yano et al. 2015
Developing novel small molecule biomarkers for clinical prediction Chumpitazi et al. 2015
Table 3 Notable applications of metabolomics in nutrition and nutrition-associated metabolic phenotyping
Applications Citations
Evaluate the impact of nutritional status of individuals on the metabolism of drugs Walter-Sack and Klotz
1996
Assess off-target effects of prescription drugs and the manner in which nutritional status impacts such effects Genser 2008
Untargeted metabolome-wide association (MWA) studies for the discovery of novel biomarkers of dietary intake for
disease-monitoring and accurate dietary assessment
Bictash et al. 2010
Assess the nutritional metabotype and how it correlates with metabotypes and genotypes of the microbiome in healthy
and diseased participants
Bictash et al. 2010
Characterize status of phase II conjugation agents (GSH, etc.), associated with drug ingestion and adverse drug events Johnson et al. 2012
Analyze how nutrition influences metabolism and homeodynamic control and how this regulation is disturbed in the
early phase of diet-related diseases
Erazo et al. 2013
Assess essential and conditionally essential micronutrient inputs, and the spreading effect of single or multiple
deficiencies (or excesses) across molecular networks
Schmidt and Goodwin
2013
Assess the connection between dietary patterns and chronic disease such as diabetes; use of dietary sensitive
metabolites to explore the links between diet and disease
Zheng et al. 2015
Assess the connection between dietary patterns and high morbidity and high mortality diseases such as cancer and
cardiovascular disease
Odriozola and Corrales
2015
Develop metabolomic biomarker panels associated with disease to assess disease-relevant metabotype Gibbons et al. 2015
Analysis of food derived metabolites and their kinetics over time Kim et al. 2016
Assess and translate metabolic changes in urine following a dietary intervention into an organ-specific, biologically
meaningful interpretation and organ-specific interpretation (plasma: similar challenges present themselves)
Schmedes et al. 2016
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integratable, as no single center currently provides the
capacity for studies of the scale envisioned for the PMI
Cohort. Without standardization there will be no ability to
take data across sites and compare/integrate. These new
forays have allowed knowledge from metabolic profiling
studies to be synergistically applied to studies where only
genomic and transcriptomic data were previously available.
Although this combined ‘omics strategy is being applied
to enhance metabolic phenotyping in a holistic approach
with relative quantification data created, the application of
multiple (semi)-targeted assays for each sample provides a
robust approach for absolute quantification of more limited
metabolite panels (hundreds, not thousands). For example,
the company Biocrates commercially supplies kits for
analysis of targeted areas of metabolism. The Biocrates
p180 kit measures amino acids, biogenic amines and 150
lipids and has been shown to be useful for evaluating dry
blood spots (Biocrates Life Sciences 2016). The Biocrates
bile acid kit can provide absolute quantification of 16 bile
acids found in humans.
Each kit provides advantages in interlaboratory use and
limitations in terms of the number of metabolites studied
(where holistic untargeted approaches are far more com-
prehensive) and the type of quantitative information
obtained (untargeted MS-based profiling provides relative
differences in metabolite levels, targeted profiling provides
absolute levels). Importantly, there is no single assay that
can detect all metabolites present in a given sample, nor do
we even currently know how many distinct molecules can
be quantified. At present, the metabolome can be viewed as
a biomedical frontier with important opportunities to
inform on systemic processes that provide the underpinning
for the coming revolution in precision medicine. Employ-
ing a combination of hydrophobic and hydrophilic chro-
matography with both positive- and negative-ion
monitoring mass spectrometric detection, it is possible to
detect 3000–4000 distinct molecules using as little as
1–20 ll of plasma (Chen et al. 2012). To take advantage of
such recent analytical breakthroughs, the metabolomics
community strongly recommends a combination of tar-
geted and untargeted strategies to maximize information
that can now be obtained from of an individual patient
sample or sample cohort.
Major developments are expected in metabolic profiling
during the next 3–5 years, as analytical approaches, com-
pound identification, ion mobility, and derivatization
agents are further developed. Major drives in metabolomics
toward greater metabolome coverage, higher sensitivity
and even smaller sample volumes—eventually envisioned
to culminate in capabilities for single cell metabolomics.
Bottlenecks are now evident in reconciling data obtained
from different laboratories, though significant efforts to
eliminate these are underway globally, including
enhancements in data standardization, quality assurance
(Dunn et al. 2012; Godzien et al. 2015) and high-confi-
dence metabolite identification (Dunn et al. 2013); indeed
the international Metabolomics Society has three separate
task groups focused on driving community use and coop-
eration in overcoming these bottlenecks (Metabolomics
Society 2014).
The type of sample being studied is always a key
component in any experimental design and the choice of
sample is obviously dependent on the biological question.
In large-scale cohort studies, biofluids (e.g., serum,
plasma, urine, saliva, stool) are most commonly employed
because of their relative ease of collection, preparation
and storage. No single biofluid is appropriate for all
studies and the biological question defines the biofluid—
oral cavity diseases match to using saliva, gut microbiome
and kidney diseases match to urine whereas cardiovas-
cular diseases and drug PK studies match to serum or
plasma. K-EDTA-plasma is recommended for blood col-
lection. Importantly the metabolome analyzed has to be
representative of the metabolome collected; as metabo-
lism operates on timescales of seconds and minutes in
enzyme-containing samples and as metabolites can be
chemically degraded at high temperatures or extreme pH
values, it is essential that samples are collected and pro-
cessed quickly to minimize any changes in metabolite
composition, both qualitatively and quantitatively (Barton
et al. 2008; Dunn et al. 2008). Traditionally, blood or
urine samples have been collected in clinic and processed
by trained staff for storage. However, this is time-con-
suming and costly for patients and researchers in cohort
studies where travel costs, staff costs, and laboratory costs
are required. One alternative is for participants in large
precision medicine initiatives is to collect samples in their
homes and send them frozen via express mail to a central
biobank facility, thus eliminating the need for participants
to travel and minimizing the efforts/costs of a trained
staff. The collection of dried blood or dried urine spots on
absorptive materials, followed by ambient temperature
delivery by post to storage facilities, offers the potential
for low-cost and larger-scale global metabotyping efforts
[see cityassays.org.uk 2014 for an example for targeted
analysis of vitamin D]. This emerging approach is cur-
rently being explored and may be applicable for studies
during the next few years (Koulman et al. 2014; Moco
et al. 2012). Notably, analysis of dried blood spots is
already the standard for newborn screening of inborn
errors in metabolism (Jones and Bennett 2002) and
applied in many drug metabolism studies (Garcia Boy
et al. 2008). The analysis of dried blood and urine spots
has had limited application to holistic metabolic profiling
studies as yet, but validation and adoption of this
approach is anticipated.
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3.1 Stable isotope tracing in mechanism-based
human health
Although tracer methodologies provide more inter-
pretable information and power than profiling (Fan et al.
2012), this is impractical in a large study of this kind.
However, such studies for a limited subset (for example,
cancer) using tissue biopsies including liquid biopsies
(leukocytes) can be envisaged, in which the sample is
incubated with an appropriate tracer, and the metabolism of
the tissue or cells is analyzed. Small amounts of tissue can
now be evaluated in this manner, owing to the technolog-
ical advances in mass spectrometry in particular. These
approaches become especially valuable in longitudinal
studies, for example pre- and post-therapy.
In summary, we have taken large steps over the last
15 years to allow the holistic study of metabolites in
humans to be performed. We are now at a stage, where
robust, reproducible large-scale studies of the role of
metabolites as a determinant of human subject variation are
becoming practical as goals of the PMI Cohort and other
large initiatives. Through the combination of multiple
methodologies and platforms, we can currently provide
broad coverage of the metabolome and anticipate the future
establishment of standardized approaches to be applied at
to-be-established high-throughput metabolite profiling
facilities worldwide. New developments in technology are
expected to allow for an ever-broadening scope of
metabolite coverage, dramatic enhancements in sample
throughput, establishment of normal human ranges for
diverse blood-borne metabolites and more facile ways to
move samples from the home to the clinic.
3.2 Computational medicine
Metabolic phenotyping has the potential to generate high-
volumes of complex spectral data. The process of trans-
lating this data into actionable medical information, be it
diagnostic, mechanistic, or patient stratification, requires
significant computational power and expertise. There are
currently several computational frameworks in general use
in the metabolomics community; however, none of these
methods are particularly focussed on the needs of precision
medicine (Xia et al. 2013). As a first step, large-scale
metabolic modeling permits to integrate and simulate
multiple ‘omics’ data types with metabolic networks
(Aurich and Thiele 2016), and it also enables to integrate
dietary and genetic information in addition to metabolomic
data (Heinken and Thiele 2015). The underlying metabolic
models are based on human biochemistry and as such
provide mechanistic links between genes, proteins, and
metabolites (Aurich and Thiele 2016). There are now
studies becoming available that demonstrate the potential
of metabolic modeling for precision medicine (Yizhak
et al. 2014), particularly when combined with personalized
metabolomic data (Aurich et al. 2016). We anticipate that
in the immediate future computational medicine will make
a quantum leap in practical functionality, combining the
robust requirements of classical epidemiology with the
flexibility of modern ‘‘big data’’ machine learning algo-
rithms. It will be necessary to map non-linear relationships
between metabolomic, genomic, and other omic data, and
combine the resulting profiles with bedside clinical meta-
data, producing the next generation of clinical expert
systems.
Compressing such large amounts of high-throughput
data into clinically coherent tools will be a major bottle-
neck in the development of omic precision medicine.
Moreover, an omic based prognostic/diagnostic signature
cannot be considered a viable ‘‘test’’ without an associated
robust computational model. Indeed, the Institute of Med-
icine (IOM) report Evolution of Translational Omics (In-
stitute of Medicine 2012) defines an omic’ test as ‘‘an assay
composed of or derived from multiple molecular mea-
surements and interpreted by a fully specified computa-
tional model to produce a clinically actionable result’’.
Thus, the development of rigorous statistical protocols
together with task-specific computational models is as
important to this field of research as managing the rapid
advances in technology.
3.3 Recommendations for precision medicine
initiatives
1. Collect biofluids by applying metabolomics commu-
nity agreed-upon standard operating procedures.
Include members of the metabolomics community in
working groups for establishment of optimal sample
collection, preservation, sample processing, data
acquisition, and omics’ analysis protocols.
2. Preserve samples by establishing a reliable and robust
biobanking system with strict inventory control. Sam-
ples should include plasma (EDTA, or heparin) and
preferably also serum or flash frozen samples.
3. Consider the additional collection of stool samples and
urine samples for sub studies related to nutrition, gut
microflora, and other scientifically relevant applications.
4. Establish resources and protocols for the distribution of
biobanked samples to NIH-supported research pro-
grams or similarly funded programs.
5. Establish funding opportunities to support personalized
medicine challenges using biobanked samples and both
untargeted and targeted strategies for large-scale
metabolic phenotyping studies.
6. Employ NIST Standard Reference material (SRM-
1950) plasma samples for standardization and quality
Metabolomics enables precision medicine: ‘‘A White Paper, Community Perspective’’ Page 11 of 15  149 
123
control of plasma metabolomics studies over time and
across analytical sites.
7. Develop NIST Standard Reference material for urine
and serum for standardization and quality control of
urine and serum metabolomics studies. Develop other
standard reference materials to provide additional
options.
8. Establish rigorous statistical/epidemiological protocols
and enable the development of the next generation of
computational medicine tools.
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